Clinical samples. At TGen, we established a web-based IRB-approved Health Insurance Portability and Accountability Act-compliant protocol to facilitate the collection of biospecimens from consenting patients with SCCOHT, their legal proxy if under 18 years of age or the loved ones of deceased individuals. Self-reported demographic and medical history data were also collected. At the University of British Columbia, we collected biospecimens from the Ovarian Cancer Research Program (OvCaRe) tissue bank in Vancouver, British Columbia, Canada; the University of Toronto in Toronto, Ontario, Canada; the Children's Oncology Group at Nationwide Children's Hospital in Columbus, Ohio, USA; and the Hospital de la Santa Creu i Sant Pau at the Autonomous University of Barcelona in Barcelona, Spain, using an IRB-approved protocol. All patients signed consent forms according to IRB-approved protocols. All of the specimens were SCCOHT, with four cases (SCCO-009, SCCO-010, SCCO-017 and SCCO-019) classified as large cell variants of SCCOHT in their pathology reports. Cases of small cell carcinoma of pulmonary type were excluded from the study.
Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an extremely rare, aggressive cancer affecting children and young women. We identified germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 in 69% (9/13) of SCCOHT cases in addition to SMARCA4 protein loss in 82% (14/17) of SCCOHT tumors but in only 0.4% (2/485) of other primary ovarian tumors. These data implicate SMARCA4 in SCCOHT oncogenesis.
SCCOHT occurs in young adult and pediatric patients (mean age of 24, range of 14 months to 58 years) [1] [2] [3] [4] . Most patients with SCCOHT are diagnosed at an advanced stage and do not respond to chemotherapy. More than 65% of patients succumb to their disease within 1-2 years of diagnosis 1 . SCCOHT is distinguished from more common types of ovarian cancer by its histological appearance, immunophenotype and cytogenetic characteristics 1 . Histologically, SCCOHT is composed of sheets of small, tightly packed cells with scant cytoplasm and hyperchromatic nuclei frequently interrupted by follicle-like structures 1 . SCCOHT shows a unique immunoprofile that includes expression of Wilms tumor suppressor gene 1 (WT1), epithelial membrane antigen (EMA), vimentin and cytokeratins alongside lack of expression of inhibin, chromogranin, thyroid transcription factor 1 (TTF1), S100 calcium-binding protein A1 and α-fetoprotein (AFP) 5 . Unlike most poorly differentiated, highly malignant tumors, SCCOHT is characteristically diploid, but its cellular and molecular mechanisms of pathogenesis remain poorly understood 1 .
To analyze the genetic etiology of SCCOHT, we performed nextgeneration sequencing on a series of tumors and germline samples from 12 SCCOHT cases (9 tumors with 4 matched germline samples and 3 additional germline samples) and on the SCCOHT cell line BIN-67 (ref. 6). DNA from tumor and blood specimens was analyzed using whole-genome sequencing (two matched tumor-normal pairs and the BIN-67 cell line) and whole-exome sequencing (remaining samples; Supplementary Table 1) . Stringent variant-calling methods were used to identify single-base substitutions and indels (see the Online Methods and Supplementary Table 2 for a list of the variants identified in each tumor). SMARCA4, a gene previously implicated in SCCOHT 7 , was the only recurrently mutated gene, bearing inactivating mutations in six of nine tumors and in BIN-67 cells ( Table 1) . Two tumors harbored two mutations each in SMARCA4, suggesting biallelic inactivation. The majority of the mutations affected the ATPase domain and are expected to result in truncated proteins (Fig. 1a) .
Given that SCCOHT has been reported to occur in families 1, 8, 9 and that germline mutations of SWI/SNF complex genes have also previously been reported in highly malignant pediatric cancers 10 , we evaluated SCCOHT germline samples for SMARCA4 mutations. We discovered truncating mutations in two of the seven cases examined ( Fig. 1a and Table 1 ), diagnosed at ages 9 and 10 years. The case diagnosed at 9 years bore the germline heterozygous nonsense mutation c.2935C>T (p.Arg979*), which truncates the SMARCA4 protein upstream of the helicase domain and bromodomain. Similarly, germline DNA from the case diagnosed at 10 years carried a frameshift mutation in exon 4, c.722_735delGTCCCGGCCCGGCA (p.Gly241fs), removing all essential SMARCA4 functional domains. Because we did not have matching germline DNA for five of the sequenced tumors, four of which had SMARCA4 mutations, we cannot exclude the possibility that some of the detected tumor mutations might also be present in the germ line of these cases.
To evaluate the possible functional effects of mutations on the SMARCA4 gene product, we assessed SMARCA4 protein expression in SCCOHT tumors (Supplementary Table 3 ). Immunohistochemical Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 VOLUME 46 | NUMBER 5 | MAY 2014 Nature GeNetics b r i e f c o m m u n i c a t i o n s analysis of 17 tumors (8 overlapping with the 12 cases sequenced above and an additional 9 validation cases) showed that 14 of 17 (82%) lacked SMARCA4 protein (Fig. 1b) . SMARCA4 staining was seen in only two tumors, both from pediatric cases. One of these cases had no germline SMARCA4 mutations by exome sequencing, and the mutational status of the second case was unknown. All samples with SMARCA4 mutation lacked detectable SMARCA4 protein. We also noted loss of SMARCB1 protein expression in one SCCOHT tumor (SCCO-010) that had no SMARCA4 mutations and retained SMARCA4 protein expression (Supplementary Table 3) . SMARCA4 loss was specific to tumor cells, as normal cells within the same sections showed robust SMARCA4 staining (Fig. 1b) . The antibody to SMARCA4 recognizes an epitope comprising amino acids 240-277. Excepting the p.Gly241fs alteration encoded in the germ line of SCCO-017, all alterations were predicted to yield proteins detectable by this antibody. Thus, the complete loss of SMARCA4 protein observed might be consistent with nonsense-mediated decay of mutant transcripts. Although loss of SMARCA4 protein in tumors with wild-type SMARCA4 and in tumors without multiple SMARCA4 mutations suggests that other mechanisms lead to SMARCA4 loss, neither DNA methylation nor loss of heterozygosity (LOH) contribute to SMARCA4 inactivation in these cases (Supplementary Figs. 1-3 and Supplementary Note).
To determine the specificity of SMARCA4 loss to SCCOHT, we performed immunohistochemistry for SMARCA4 in 485 primary ovarian epithelial, sex cord stromal and germ cell tumors (Supplementary Table 4 ) as well as in normal premenopausal ovary and fallopian tube (Supplementary Fig. 4 ). Only two tumors (0.4%), both clear cell carcinomas, were negative for SMARCA4 staining. Notably, the tumors that most closely resembled SCCOHT histologically, including b r i e f c o m m u n i c a t i o n s all granulosa cell tumors of juvenile (n = 8) and adult (n = 36) types, maintained SMARCA4 expression. In addition, representative cell lines from four ovarian carcinoma subtypes as well as immortalized granulosa cells (SVOGs) and adult granulosa tumor cells (KGNs) all maintained SMARCA4 expression as determined by protein blotting (Fig. 1c) . In contrast, the BIN-67 SCCOHT cell line, which harbored two splice-site mutations in SMARCA4, showed complete absence of SMARCA4 protein (Fig. 1c) . These results demonstrate that SMARCA4 loss is highly specific to SCCOHT. We have identified frequent germline and somatic SMARCA4 mutations and SMARCA4 protein loss in SCCOHT. These data suggest a tumor suppressor role for SMARCA4, reminiscent of data in which mice with conditional loss of Smarca4 develop ovarian cysts and uterine tumors 11 . The loss of normal SWI/SNF complex function might therefore represent a key tumorigenic step in SCCOHT and might further constitute a key therapeutic vulnerability in SMARCA4-deficient cells [12] [13] [14] . Finally, we have shown that loss of SMARCA4 protein expression is extremely specific to SCCOHT and can facilitate the differential diagnosis of SCCOHT.
URLs. Small cell carcinoma of the ovary (SCCO) research study, https://www.tgen.org/research/research-divisions/genetic-basis-ofhuman-disease/scco-research-study.aspx.
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Methods and any associated references are available in the online version of the paper. 
